Structured Review

R&D Systems vegf a165 b elisa
Pan–vascular endothelial growth factor <t>(VEGF)-A</t> and VEGF-A xxx b expression in the lungs of patients with idiopathic pulmonary fibrosis (IPF). ( A ) Pan-VEGF-A reverse transcription–polymerase chain reaction (RT-PCR) of whole-lung RNA extract using VEGF-A Exon2/3 For and 8b Rev primers ( top ) and Exon 7a For and 8b Rev primers ( bottom ) (n = 5 normal lung; n = 5 IPF lung). VEGF-A 121 a, VEGF-A 165 a, VEGF-A 165 b, and VEGF-A 189 a isoforms were identified by RT-PCR and verified by direct sequencing ( see Figure E1). L = 50-bp marker. ( B ) Quantitative RT-PCR of pan-VEGF-A and VEGF-A xxx b mRNA expression in whole-lung tissue homogenates of normal (n = 5) and IPF lung (n = 5). No significant difference was detected in the expression of pan-VEGF-A or VEGF-A 165 b (unpaired Student’s t test) isoforms between normal and IPF lung samples. ( C ) Pan-VEGF-A and VEGF-A 165 b <t>ELISA</t> data from lung whole-tissue lysates in normal (n = 5) and IPF (n = 5) subjects. There was no significant difference in pan-VEGF-A expression (unpaired Student’s t test with Welch correction), but a significant increase in VEGF-A 165 b expression in the IPF lung was observed (**** P
Vegf A165 B Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vegf a165 b elisa/product/R&D Systems
Average 97 stars, based on 1 article reviews
Price from $9.99 to $1999.99
vegf a165 b elisa - by Bioz Stars, 2021-07
97/100 stars

Images

1) Product Images from "Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis"

Article Title: Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis

Journal: American Journal of Respiratory and Critical Care Medicine

doi: 10.1164/rccm.201603-0568OC

Pan–vascular endothelial growth factor (VEGF)-A and VEGF-A xxx b expression in the lungs of patients with idiopathic pulmonary fibrosis (IPF). ( A ) Pan-VEGF-A reverse transcription–polymerase chain reaction (RT-PCR) of whole-lung RNA extract using VEGF-A Exon2/3 For and 8b Rev primers ( top ) and Exon 7a For and 8b Rev primers ( bottom ) (n = 5 normal lung; n = 5 IPF lung). VEGF-A 121 a, VEGF-A 165 a, VEGF-A 165 b, and VEGF-A 189 a isoforms were identified by RT-PCR and verified by direct sequencing ( see Figure E1). L = 50-bp marker. ( B ) Quantitative RT-PCR of pan-VEGF-A and VEGF-A xxx b mRNA expression in whole-lung tissue homogenates of normal (n = 5) and IPF lung (n = 5). No significant difference was detected in the expression of pan-VEGF-A or VEGF-A 165 b (unpaired Student’s t test) isoforms between normal and IPF lung samples. ( C ) Pan-VEGF-A and VEGF-A 165 b ELISA data from lung whole-tissue lysates in normal (n = 5) and IPF (n = 5) subjects. There was no significant difference in pan-VEGF-A expression (unpaired Student’s t test with Welch correction), but a significant increase in VEGF-A 165 b expression in the IPF lung was observed (**** P
Figure Legend Snippet: Pan–vascular endothelial growth factor (VEGF)-A and VEGF-A xxx b expression in the lungs of patients with idiopathic pulmonary fibrosis (IPF). ( A ) Pan-VEGF-A reverse transcription–polymerase chain reaction (RT-PCR) of whole-lung RNA extract using VEGF-A Exon2/3 For and 8b Rev primers ( top ) and Exon 7a For and 8b Rev primers ( bottom ) (n = 5 normal lung; n = 5 IPF lung). VEGF-A 121 a, VEGF-A 165 a, VEGF-A 165 b, and VEGF-A 189 a isoforms were identified by RT-PCR and verified by direct sequencing ( see Figure E1). L = 50-bp marker. ( B ) Quantitative RT-PCR of pan-VEGF-A and VEGF-A xxx b mRNA expression in whole-lung tissue homogenates of normal (n = 5) and IPF lung (n = 5). No significant difference was detected in the expression of pan-VEGF-A or VEGF-A 165 b (unpaired Student’s t test) isoforms between normal and IPF lung samples. ( C ) Pan-VEGF-A and VEGF-A 165 b ELISA data from lung whole-tissue lysates in normal (n = 5) and IPF (n = 5) subjects. There was no significant difference in pan-VEGF-A expression (unpaired Student’s t test with Welch correction), but a significant increase in VEGF-A 165 b expression in the IPF lung was observed (**** P

Techniques Used: Expressing, Reverse Transcription Polymerase Chain Reaction, Sequencing, Marker, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

The effect of vascular endothelial growth factor (VEGF)-A 165 b on the development of pulmonary fibrosis. ( A ) Lung phenotype of the MMTV-VEGF-A 165 b transgenic (TG) mouse. Immunohistochemical staining for VEGF-A 165 b in the lung of TG mice with quantification of VEGF-A 165 b expression by ELISA, in whole-tissue lysates and bronchoalveolar lavage fluid (BALF). VEGF-A 165 b expression was increased in the alveolar type II (ATII) cells of the TG mouse lung ( d and f , indicated by arrows ) compared with the wild-type (WT) lung ( c and e ). Isotype IgG staining was used as a negative control ( a and b ). Images were taken at ×100 magnification; scale bars = 10 μm, (n = 3, n = 1 shown). VEGF-A 165 b expression was significantly up-regulated in whole-tissue lysates of TG mice compared with WT mice (* P
Figure Legend Snippet: The effect of vascular endothelial growth factor (VEGF)-A 165 b on the development of pulmonary fibrosis. ( A ) Lung phenotype of the MMTV-VEGF-A 165 b transgenic (TG) mouse. Immunohistochemical staining for VEGF-A 165 b in the lung of TG mice with quantification of VEGF-A 165 b expression by ELISA, in whole-tissue lysates and bronchoalveolar lavage fluid (BALF). VEGF-A 165 b expression was increased in the alveolar type II (ATII) cells of the TG mouse lung ( d and f , indicated by arrows ) compared with the wild-type (WT) lung ( c and e ). Isotype IgG staining was used as a negative control ( a and b ). Images were taken at ×100 magnification; scale bars = 10 μm, (n = 3, n = 1 shown). VEGF-A 165 b expression was significantly up-regulated in whole-tissue lysates of TG mice compared with WT mice (* P

Techniques Used: Transgenic Assay, Immunohistochemistry, Staining, Mouse Assay, Expressing, Enzyme-linked Immunosorbent Assay, Negative Control

Related Articles

Enzyme-linked Immunosorbent Assay:

Article Title: The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy
Article Snippet: Furthermore, VEGF-A165 b expression inhibits VEGF-A165 -mediated proliferation, migration and vasodilation in vitro [ , , ] as well as in vivo models of angiogenesis including rat mesentery and rabbit cornea [ ], mouse skin and chick chorioallantoic membrane [ ], Matrigel implants [ ], rat mammary gland [ ], rat ovary [ ] and tumour models [ , ]. .. The ability to detect VEGF-A in biological samples is critical for the assessment of angiogenesis and commercial pan VEGF-A ELISA kits are widely available, with the R & D Systems ELISA (DY293B, R & D Systems) one of the most commonly cited. .. A method for VEGF-Axxx b isoform detection in both laboratory and medical samples has already been established [ , , ] and a commercial version has been available for several years (DY3045, R & D Systems).

Article Title: Altered ratios of pro‐ and anti‐angiogenic VEGF‐A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma
Article Snippet: The cells were serum‐starved with EBM‐2 medium for 12–16 h prior to VEGF‐A treatments, then lysed in lysis buffer (200 mm NaCl, 75 mm Trizma base, 1 mm EDTA, 1.5% Triton X, 0.75% Np‐40, 15 mm NaF and 1.5 mm Na3 VO4 ; Sigma‐Aldrich) on ice for 5 min and subjected to standard immunoblotting (antibody details and blotting conditions are described in Supplementary materials and methods, see supplementary material). .. VEGF‐A ELISA VEGF‐A and VEGF‐A165 b protein levels were assessed using human VEGF‐A and VEGF‐A165 b DuoSet (R & D Systems), following the manufacturer's instructions. .. Polymerase chain reaction ( PCR ) RNA was extracted with TRI‐reagent (Invitrogen); all materials, except primers, were purchased from Promega; 1 µg RNA was DNase‐treated and reverse‐transcribed with M‐MLV reverse transcriptase.

Article Title: Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis
Article Snippet: Endogenous peroxidases were blocked and sections incubated with primary antibody or IgG control. .. Pan-VEGF-A and VEGF-A165 b levels were quantified using Pan-VEGF-A and VEGF-A165 b ELISA sets (R & D Systems, Oxford, UK). .. Fibroblasts were seeded into 24-well plates or IBIDI culture chambers (Ibidi, Martinsried, Germany); quiesced; and after stimulation, counted or imaged.

Concentration Assay:

Article Title: Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios
Article Snippet: Plasma samples were assessed for expression of both VEGF-Axxx b and panVEGF-A, a measure of both VEGF-Axxx and VEGF-Axxx b isoforms, using Enzyme-Linked Immunosorbent Assay (ELISA). .. An Immunoassay 96 well plate (Thermo Life Sciences) was coated with a mouse anti-VEGF-A165 b monoclonal antibody (Clone 56/1, MAB3045, R & D Systems) at a concentration of 10 µg/ml, covered with parafilm and protected from light, then left shaking at room temperature (RT) overnight (~16 hours). pan VEGF-A capture was mouse anti-VEGF-A monoclonal antibody at 2 µg/ml (MAB293, R & D Systems). ..

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    R&D Systems vegf a165 b elisa
    Pan–vascular endothelial growth factor <t>(VEGF)-A</t> and VEGF-A xxx b expression in the lungs of patients with idiopathic pulmonary fibrosis (IPF). ( A ) Pan-VEGF-A reverse transcription–polymerase chain reaction (RT-PCR) of whole-lung RNA extract using VEGF-A Exon2/3 For and 8b Rev primers ( top ) and Exon 7a For and 8b Rev primers ( bottom ) (n = 5 normal lung; n = 5 IPF lung). VEGF-A 121 a, VEGF-A 165 a, VEGF-A 165 b, and VEGF-A 189 a isoforms were identified by RT-PCR and verified by direct sequencing ( see Figure E1). L = 50-bp marker. ( B ) Quantitative RT-PCR of pan-VEGF-A and VEGF-A xxx b mRNA expression in whole-lung tissue homogenates of normal (n = 5) and IPF lung (n = 5). No significant difference was detected in the expression of pan-VEGF-A or VEGF-A 165 b (unpaired Student’s t test) isoforms between normal and IPF lung samples. ( C ) Pan-VEGF-A and VEGF-A 165 b <t>ELISA</t> data from lung whole-tissue lysates in normal (n = 5) and IPF (n = 5) subjects. There was no significant difference in pan-VEGF-A expression (unpaired Student’s t test with Welch correction), but a significant increase in VEGF-A 165 b expression in the IPF lung was observed (**** P
    Vegf A165 B Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf a165 b elisa/product/R&D Systems
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf a165 b elisa - by Bioz Stars, 2021-07
    97/100 stars
      Buy from Supplier

    90
    R&D Systems ng g recombinant human
    Systemic <t>VEGF-A</t> 165 b prevents diabetes-induced increase in solute flux ( A ) Sprague–Dawley female rats were induced with diabetes using STZ (50 mg/kg i.p., n =10) and control rats ( n =5) were injected with saline (i.p.) on day 0. After 4 days, blood glucose was tested and blood glucose ≥ 15mmol/l were deemed diabetic. ( B ) Diabetic rats were treated with either vehicle (saline, biweekly i.p., n =5) or VEGF-A 165 b (20 <t>ng/g,</t> biweekly i.p., n =5). At 8 weeks post-STZ induction, Evans Blue (EB, 45 mg/kg) was injected i.v. into terminally anaesthetized rats. Plasma was collected every 15 minutes for 2 h, after which, animals were killed and retinae were excised. ( C ) Retinae were weighed and EB was extracted using formamide, allowing EB solute flux (C) and permeability surface area product ( D ) to be calculated; Kruskal–Wallis test with Dunn's post-hoc test, ** p
    Ng G Recombinant Human, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ng g recombinant human/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ng g recombinant human - by Bioz Stars, 2021-07
    90/100 stars
      Buy from Supplier

    86
    R&D Systems vegf a165 b
    Systemic <t>VEGF-A</t> 165 b prevents diabetes-induced increase in solute flux ( A ) Sprague–Dawley female rats were induced with diabetes using STZ (50 mg/kg i.p., n =10) and control rats ( n =5) were injected with saline (i.p.) on day 0. After 4 days, blood glucose was tested and blood glucose ≥ 15mmol/l were deemed diabetic. ( B ) Diabetic rats were treated with either vehicle (saline, biweekly i.p., n =5) or VEGF-A 165 b (20 <t>ng/g,</t> biweekly i.p., n =5). At 8 weeks post-STZ induction, Evans Blue (EB, 45 mg/kg) was injected i.v. into terminally anaesthetized rats. Plasma was collected every 15 minutes for 2 h, after which, animals were killed and retinae were excised. ( C ) Retinae were weighed and EB was extracted using formamide, allowing EB solute flux (C) and permeability surface area product ( D ) to be calculated; Kruskal–Wallis test with Dunn's post-hoc test, ** p
    Vegf A165 B, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf a165 b/product/R&D Systems
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf a165 b - by Bioz Stars, 2021-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Pan–vascular endothelial growth factor (VEGF)-A and VEGF-A xxx b expression in the lungs of patients with idiopathic pulmonary fibrosis (IPF). ( A ) Pan-VEGF-A reverse transcription–polymerase chain reaction (RT-PCR) of whole-lung RNA extract using VEGF-A Exon2/3 For and 8b Rev primers ( top ) and Exon 7a For and 8b Rev primers ( bottom ) (n = 5 normal lung; n = 5 IPF lung). VEGF-A 121 a, VEGF-A 165 a, VEGF-A 165 b, and VEGF-A 189 a isoforms were identified by RT-PCR and verified by direct sequencing ( see Figure E1). L = 50-bp marker. ( B ) Quantitative RT-PCR of pan-VEGF-A and VEGF-A xxx b mRNA expression in whole-lung tissue homogenates of normal (n = 5) and IPF lung (n = 5). No significant difference was detected in the expression of pan-VEGF-A or VEGF-A 165 b (unpaired Student’s t test) isoforms between normal and IPF lung samples. ( C ) Pan-VEGF-A and VEGF-A 165 b ELISA data from lung whole-tissue lysates in normal (n = 5) and IPF (n = 5) subjects. There was no significant difference in pan-VEGF-A expression (unpaired Student’s t test with Welch correction), but a significant increase in VEGF-A 165 b expression in the IPF lung was observed (**** P

    Journal: American Journal of Respiratory and Critical Care Medicine

    Article Title: Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis

    doi: 10.1164/rccm.201603-0568OC

    Figure Lengend Snippet: Pan–vascular endothelial growth factor (VEGF)-A and VEGF-A xxx b expression in the lungs of patients with idiopathic pulmonary fibrosis (IPF). ( A ) Pan-VEGF-A reverse transcription–polymerase chain reaction (RT-PCR) of whole-lung RNA extract using VEGF-A Exon2/3 For and 8b Rev primers ( top ) and Exon 7a For and 8b Rev primers ( bottom ) (n = 5 normal lung; n = 5 IPF lung). VEGF-A 121 a, VEGF-A 165 a, VEGF-A 165 b, and VEGF-A 189 a isoforms were identified by RT-PCR and verified by direct sequencing ( see Figure E1). L = 50-bp marker. ( B ) Quantitative RT-PCR of pan-VEGF-A and VEGF-A xxx b mRNA expression in whole-lung tissue homogenates of normal (n = 5) and IPF lung (n = 5). No significant difference was detected in the expression of pan-VEGF-A or VEGF-A 165 b (unpaired Student’s t test) isoforms between normal and IPF lung samples. ( C ) Pan-VEGF-A and VEGF-A 165 b ELISA data from lung whole-tissue lysates in normal (n = 5) and IPF (n = 5) subjects. There was no significant difference in pan-VEGF-A expression (unpaired Student’s t test with Welch correction), but a significant increase in VEGF-A 165 b expression in the IPF lung was observed (**** P

    Article Snippet: Pan-VEGF-A and VEGF-A165 b levels were quantified using Pan-VEGF-A and VEGF-A165 b ELISA sets (R & D Systems, Oxford, UK).

    Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Sequencing, Marker, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

    The effect of vascular endothelial growth factor (VEGF)-A 165 b on the development of pulmonary fibrosis. ( A ) Lung phenotype of the MMTV-VEGF-A 165 b transgenic (TG) mouse. Immunohistochemical staining for VEGF-A 165 b in the lung of TG mice with quantification of VEGF-A 165 b expression by ELISA, in whole-tissue lysates and bronchoalveolar lavage fluid (BALF). VEGF-A 165 b expression was increased in the alveolar type II (ATII) cells of the TG mouse lung ( d and f , indicated by arrows ) compared with the wild-type (WT) lung ( c and e ). Isotype IgG staining was used as a negative control ( a and b ). Images were taken at ×100 magnification; scale bars = 10 μm, (n = 3, n = 1 shown). VEGF-A 165 b expression was significantly up-regulated in whole-tissue lysates of TG mice compared with WT mice (* P

    Journal: American Journal of Respiratory and Critical Care Medicine

    Article Title: Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis

    doi: 10.1164/rccm.201603-0568OC

    Figure Lengend Snippet: The effect of vascular endothelial growth factor (VEGF)-A 165 b on the development of pulmonary fibrosis. ( A ) Lung phenotype of the MMTV-VEGF-A 165 b transgenic (TG) mouse. Immunohistochemical staining for VEGF-A 165 b in the lung of TG mice with quantification of VEGF-A 165 b expression by ELISA, in whole-tissue lysates and bronchoalveolar lavage fluid (BALF). VEGF-A 165 b expression was increased in the alveolar type II (ATII) cells of the TG mouse lung ( d and f , indicated by arrows ) compared with the wild-type (WT) lung ( c and e ). Isotype IgG staining was used as a negative control ( a and b ). Images were taken at ×100 magnification; scale bars = 10 μm, (n = 3, n = 1 shown). VEGF-A 165 b expression was significantly up-regulated in whole-tissue lysates of TG mice compared with WT mice (* P

    Article Snippet: Pan-VEGF-A and VEGF-A165 b levels were quantified using Pan-VEGF-A and VEGF-A165 b ELISA sets (R & D Systems, Oxford, UK).

    Techniques: Transgenic Assay, Immunohistochemistry, Staining, Mouse Assay, Expressing, Enzyme-linked Immunosorbent Assay, Negative Control

    Systemic VEGF-A 165 b prevents diabetes-induced increase in solute flux ( A ) Sprague–Dawley female rats were induced with diabetes using STZ (50 mg/kg i.p., n =10) and control rats ( n =5) were injected with saline (i.p.) on day 0. After 4 days, blood glucose was tested and blood glucose ≥ 15mmol/l were deemed diabetic. ( B ) Diabetic rats were treated with either vehicle (saline, biweekly i.p., n =5) or VEGF-A 165 b (20 ng/g, biweekly i.p., n =5). At 8 weeks post-STZ induction, Evans Blue (EB, 45 mg/kg) was injected i.v. into terminally anaesthetized rats. Plasma was collected every 15 minutes for 2 h, after which, animals were killed and retinae were excised. ( C ) Retinae were weighed and EB was extracted using formamide, allowing EB solute flux (C) and permeability surface area product ( D ) to be calculated; Kruskal–Wallis test with Dunn's post-hoc test, ** p

    Journal: Clinical Science (London, England : 1979)

    Article Title: Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina

    doi: 10.1042/CS20170102

    Figure Lengend Snippet: Systemic VEGF-A 165 b prevents diabetes-induced increase in solute flux ( A ) Sprague–Dawley female rats were induced with diabetes using STZ (50 mg/kg i.p., n =10) and control rats ( n =5) were injected with saline (i.p.) on day 0. After 4 days, blood glucose was tested and blood glucose ≥ 15mmol/l were deemed diabetic. ( B ) Diabetic rats were treated with either vehicle (saline, biweekly i.p., n =5) or VEGF-A 165 b (20 ng/g, biweekly i.p., n =5). At 8 weeks post-STZ induction, Evans Blue (EB, 45 mg/kg) was injected i.v. into terminally anaesthetized rats. Plasma was collected every 15 minutes for 2 h, after which, animals were killed and retinae were excised. ( C ) Retinae were weighed and EB was extracted using formamide, allowing EB solute flux (C) and permeability surface area product ( D ) to be calculated; Kruskal–Wallis test with Dunn's post-hoc test, ** p

    Article Snippet: For the chronic experiment, diabetic rats were treated with 20 ng/g recombinant human (rh)VEGF-A165 b (i.p., R & D Systems, MN, U.S.A.) or saline biweekly for the experimental period.

    Techniques: Injection, Permeability

    VEGF-A 165 b prevents retinal ganglion cell shrinkage ( A ) Sprague–Dawley rats induced with diabetes were treated with vehicle (saline i.p., n =4) or VEGF-A 165 b (20 ng/g i.p., n =4) biweekly for 8 weeks. Animals were then killed and retinae excised and ( A ) stained for RGC marker NeuN. RGC NeuN+ staining was counted ( B ) and areas measured ( C ). ( D ) The frequency of NeuN+ areas (50 μm bins) was plotted against area, and Lorentzian curve fitted, and curve fit compared with an F -test; P

    Journal: Clinical Science (London, England : 1979)

    Article Title: Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina

    doi: 10.1042/CS20170102

    Figure Lengend Snippet: VEGF-A 165 b prevents retinal ganglion cell shrinkage ( A ) Sprague–Dawley rats induced with diabetes were treated with vehicle (saline i.p., n =4) or VEGF-A 165 b (20 ng/g i.p., n =4) biweekly for 8 weeks. Animals were then killed and retinae excised and ( A ) stained for RGC marker NeuN. RGC NeuN+ staining was counted ( B ) and areas measured ( C ). ( D ) The frequency of NeuN+ areas (50 μm bins) was plotted against area, and Lorentzian curve fitted, and curve fit compared with an F -test; P

    Article Snippet: For the chronic experiment, diabetic rats were treated with 20 ng/g recombinant human (rh)VEGF-A165 b (i.p., R & D Systems, MN, U.S.A.) or saline biweekly for the experimental period.

    Techniques: Staining, Marker

    VEGF-A 165 b prevents diabetes-induced increase in retinal vascular density ( A ) STZ (50 mg/kg, i.p.) was used to induce diabetes in Sprague–Dawley rats ( n =10). Saline was injected in vehicle controls (i.p., n =4). Diabetic rats were either treated with VEGF-A 165 b (20 ng/g, biweekly i.p., n =5) or saline (biweekly i.p., n =5). All groups were weighed weekly and rats with a blood glucose ≥15 mmol/l were deemed diabetic. ( B ) Rats were killed at 8 weeks and retinae were stained for blood vessels using IB4 and DAPI. Vascular density was calculated from three parts of the retina in each animal (denoted by shading) using Imaris software, measured as both area ( C ) and volume ( D ) occupied by vasculature in a 2D and 3D plane respectively. This was corroborated by measuring integrated density on Fiji software ( E ). Retinae were also assessed for vessel straightness using Imaris software as a marker for vessel tortuosity ( F ); one-way ANOVA, Tukey's post-hoc test, * p

    Journal: Clinical Science (London, England : 1979)

    Article Title: Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina

    doi: 10.1042/CS20170102

    Figure Lengend Snippet: VEGF-A 165 b prevents diabetes-induced increase in retinal vascular density ( A ) STZ (50 mg/kg, i.p.) was used to induce diabetes in Sprague–Dawley rats ( n =10). Saline was injected in vehicle controls (i.p., n =4). Diabetic rats were either treated with VEGF-A 165 b (20 ng/g, biweekly i.p., n =5) or saline (biweekly i.p., n =5). All groups were weighed weekly and rats with a blood glucose ≥15 mmol/l were deemed diabetic. ( B ) Rats were killed at 8 weeks and retinae were stained for blood vessels using IB4 and DAPI. Vascular density was calculated from three parts of the retina in each animal (denoted by shading) using Imaris software, measured as both area ( C ) and volume ( D ) occupied by vasculature in a 2D and 3D plane respectively. This was corroborated by measuring integrated density on Fiji software ( E ). Retinae were also assessed for vessel straightness using Imaris software as a marker for vessel tortuosity ( F ); one-way ANOVA, Tukey's post-hoc test, * p

    Article Snippet: For the chronic experiment, diabetic rats were treated with 20 ng/g recombinant human (rh)VEGF-A165 b (i.p., R & D Systems, MN, U.S.A.) or saline biweekly for the experimental period.

    Techniques: Injection, Staining, Software, Marker